CAJ | 학술논문

　　目的分析宫颈液基薄层细胞学TCT检测结果为未有明确意义的不典型鳞状上皮细胞（ASCUS）患者的临床与病理结果，探讨其临床意义及处理方式。方法回顾性分析2012年1～6月在我院接受宫颈液基薄层细胞学TCT检查并报告为ASCUS的293例患者，同时进行13种高危型HPV-DNA检测及阴道镜评估与镜下活检。结果在293例ASCUS患者中，高危型HPV-DNA检测阳性235例（80.20%），阴性58例（19.80%）；经组织病理学证实：高级别CIN 24例，宫颈癌1例，湿疣19例，CIN 1和宫颈炎分别为62例、187例；HPV阳性组CIN检出率高于阴性组，两组比较差异有统计学意义（P＜0.05）；阴道镜检查与病理结果符合率为57.62%。结论宫颈细胞学报告为ASCUS患者，其组织病理活检结果差异大，应引起重视；HPV检测及阴道镜评估、活检可以进一步帮助明确诊断，并可为患者提供合理有效的处理方案。
　　목적분석궁경액기박층세포학TCT검측결과위미유명학의의적불전형린상상피세포（ASCUS）환자적림상여병리결과，탐토기림상의의급처리방식。방법회고성분석2012년1～6월재아원접수궁경액기박층세포학TCT검사병보고위ASCUS적293례환자，동시진행13충고위형HPV-DNA검측급음도경평고여경하활검。결과재293례ASCUS환자중，고위형HPV-DNA검측양성235례（80.20%），음성58례（19.80%）；경조직병이학증실：고급별CIN 24례，궁경암1례，습우19례，CIN 1화궁경염분별위62례、187례；HPV양성조CIN검출솔고우음성조，량조비교차이유통계학의의（P＜0.05）；음도경검사여병리결과부합솔위57.62%。결론궁경세포학보고위ASCUS환자，기조직병리활검결과차이대，응인기중시；HPV검측급음도경평고、활검가이진일보방조명학진단，병가위환자제공합리유효적처리방안。
Objective To explore the clinical significance and treatment principles of cervical ASCUS. Methods 293 cases of cervical ASCUS were performed by both the Hybrid Capture II (HC-II) assay for detecting 13 types of high-risk HPV-DNA and colposcopic biopsy test from January to June 2012, then analysis the clinical and pathology results.Results Of the 293 cases, the positive rate of 13 types of high-risk HPV-DNA was 80.20% (235/293), negative rate was 19.80%(58/293). Among them, 24 cases were high grade CIN, 1 case squamous cell carcinoma, 19 cases of simple condyloma lesions, 62 cases of CIN 1 and 187 cases of inflammation respectively; Detection rate of CIN in HPV-DNA positive group (80/235) was higher than that in negative group (7/58). There was statistical significance between the positive group of HPV-DNA and the negative group (P<0.05). The diagnostic accordance rate of colposcopy results and pathological biopsy results was 57.62%. Conclusion For the patients with cervical ASCUS, because of the biopsy results in changes is larger, more attention should be paid to. HPV-DNA detection and colposcopy assessment, pathology biopsy may be helpful for the diagnosis and can provide a reasonable and effective treatment scheme for patients.